FdaApplication
BLA 761062
Identifiers
- fda_app_no: BLA761062
Properties
| Property | Value |
|---|---|
| applicant_name | Amgen Inc. |
| application_type | BLA |
| approval_date | 2019-04-09 |
Revenue by product
EVENITY
| Period | Revenue |
|---|---|
| Q2 2026 | $714.0M |
| Q1 2026 | $562.0M |
| Q4 2025 | $599.0M |
| Q3 2025 | $541.0M |
| Q2 2025 | $518.0M |
| Q1 2025 | $442.0M |
| Q4 2024 | $431.0M |
| Q3 2024 | $399.0M |
| Q2 2024 | $391.0M |
| Q1 2024 | $342.0M |
| Q4 2023 | $318.0M |
| Q3 2023 | $307.0M |
| Q2 2023 | $281.0M |
| Q1 2023 | $254.0M |
| Q4 2022 | $225.0M |
| Q3 2022 | $201.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EVENITY | ROMOSOZUMAB-AQQG | 105MG/1.17ML | Injection |
1 product